BRPI0607433A2 - composto ou um sal do mesmo, pró-droga, agente farmacêutico, inibidor de peptidase, uso de um composto ou de uma pró-droga do mesmo, e, métodos de prevenção ou tratamento de doenças, de inibição de peptidase em um mamìfero, e de produção de um composto - Google Patents
composto ou um sal do mesmo, pró-droga, agente farmacêutico, inibidor de peptidase, uso de um composto ou de uma pró-droga do mesmo, e, métodos de prevenção ou tratamento de doenças, de inibição de peptidase em um mamìfero, e de produção de um compostoInfo
- Publication number
- BRPI0607433A2 BRPI0607433A2 BRPI0607433-2A BRPI0607433A BRPI0607433A2 BR PI0607433 A2 BRPI0607433 A2 BR PI0607433A2 BR PI0607433 A BRPI0607433 A BR PI0607433A BR PI0607433 A2 BRPI0607433 A2 BR PI0607433A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- optionally substituted
- peptidase
- prodrug
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
COMPOSTO OU UM SAL DO MESMO, PRó-DROGA, AGENTE FARMACêUTICO, INIBIDOR DE PEPTIDASE, USO DE UM COMPOSTO OU DE UMA PRó-DROGA DO MESMO, E, METODOS DE PREVENçãO OU TRATAMENTO DE DOENçAS, DE INIBIçãO DE PEPTIDASE EM UM MAMìFERO, E DE PRODUçãO DE UM COMPOSTO. A invenção refere-se a um composto representado pela fórmula (1): em que R^ 1^ é um grupo C~ 1-6~ alquil opcionalmente substituído por um grupo C~ 3-10~ cicloalquil, R^ 2^ é um grupo C~ 2-6~ alquil, R^ 3^ é um átomo de hidrogênio, um grupo C~ 1-6~ alquil ou um átomo de halogénio, e X é -OR^ 6^ ou - NR^ 4^R^ 5^ em que R^ 4^ e R^ 6^ são, cada um, independentemente, um átomo de hidrogênio, um grupo hidrocarboneto opcionalmente substituído ou um grupo heterocíclico opcionalmente substituído, R^ 5^ é um grupo hidrocarboneto opcionalmente substituído, um grupo heterocíclico opcionalmente substituído ou um grupo hidroxi opcionalmente substituído, ou R^ 4^ e R^ 5^ opcionalmente formam, juntamente com o átomo de nitrogênio adjacente, um heterociclo contendo nitrogênio opcionalmente substituído, ou um sal do mesmo. O composto da presente invenção tem uma ação inibidora de peptidase superior e é útil como um agente para a profilaxia ou tratamento de diabetes, e semelhantes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005052018 | 2005-02-25 | ||
PCT/JP2006/304177 WO2006090915A1 (en) | 2005-02-25 | 2006-02-24 | Pyridyl acetic acid compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0607433A2 true BRPI0607433A2 (pt) | 2009-09-08 |
Family
ID=36370977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0607433-2A BRPI0607433A2 (pt) | 2005-02-25 | 2006-02-24 | composto ou um sal do mesmo, pró-droga, agente farmacêutico, inibidor de peptidase, uso de um composto ou de uma pró-droga do mesmo, e, métodos de prevenção ou tratamento de doenças, de inibição de peptidase em um mamìfero, e de produção de um composto |
Country Status (17)
Country | Link |
---|---|
US (1) | US20090088419A1 (pt) |
EP (1) | EP1851202A1 (pt) |
KR (1) | KR20070106794A (pt) |
CN (1) | CN101166725A (pt) |
AR (1) | AR055563A1 (pt) |
AU (1) | AU2006217677A1 (pt) |
BR (1) | BRPI0607433A2 (pt) |
CA (1) | CA2598934A1 (pt) |
CR (1) | CR9369A (pt) |
IL (1) | IL185399A0 (pt) |
MA (1) | MA29323B1 (pt) |
NO (1) | NO20074668L (pt) |
PE (1) | PE20061099A1 (pt) |
RU (1) | RU2007135339A (pt) |
TW (1) | TW200640862A (pt) |
WO (1) | WO2006090915A1 (pt) |
ZA (1) | ZA200708144B (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME00535B (me) | 2006-06-27 | 2011-10-10 | Takeda Pharmaceuticals Co | Fuzionisana ciklična jedinjenja |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
EP2308847B1 (en) | 2009-10-09 | 2014-04-02 | EMC microcollections GmbH | Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases |
US8648073B2 (en) | 2009-12-30 | 2014-02-11 | Fochon Pharma, Inc. | Certain dipeptidyl peptidase inhibitors |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2014064215A1 (en) | 2012-10-24 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL |
US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
CN109305957B (zh) * | 2017-07-26 | 2021-08-03 | 上海医药工业研究院 | 苯基吡啶类化合物及其在dpp-4酶抑制剂的应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ253742A (en) * | 1992-07-03 | 1997-06-24 | Smithkline Beecham Plc | Heterocyclylaminoalkoxy substituted phenyl derivatives and pharmaceutical compositions |
US5827865A (en) * | 1995-03-09 | 1998-10-27 | Smithkline Beecham P.L.C. | Heterocyclic compounds as pharmaceutical |
US6291495B1 (en) * | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
WO2001021577A2 (en) * | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
PL371678A1 (en) * | 2002-02-13 | 2005-06-27 | F.Hoffmann-La Roche Ag | Novel pyridin- and pyrimidin-derivatives |
AU2003254852A1 (en) * | 2002-08-08 | 2004-02-25 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds as peptidase inhibitors |
JP4400563B2 (ja) * | 2003-02-13 | 2010-01-20 | 萬有製薬株式会社 | 新規2−ピリジンカルボキサミド誘導体 |
TW200523252A (en) * | 2003-10-31 | 2005-07-16 | Takeda Pharmaceutical | Pyridine compounds |
RU2367659C2 (ru) * | 2003-11-05 | 2009-09-20 | Ф.Хоффманн-Ля Рош Аг | Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar) |
BRPI0416283A (pt) * | 2003-11-05 | 2007-01-23 | Hoffmann La Roche | compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos |
-
2006
- 2006-02-24 EP EP06715236A patent/EP1851202A1/en not_active Withdrawn
- 2006-02-24 CA CA002598934A patent/CA2598934A1/en not_active Abandoned
- 2006-02-24 TW TW095106239A patent/TW200640862A/zh unknown
- 2006-02-24 CN CNA2006800139906A patent/CN101166725A/zh active Pending
- 2006-02-24 ZA ZA200708144A patent/ZA200708144B/xx unknown
- 2006-02-24 KR KR1020077021956A patent/KR20070106794A/ko not_active Application Discontinuation
- 2006-02-24 AU AU2006217677A patent/AU2006217677A1/en not_active Abandoned
- 2006-02-24 BR BRPI0607433-2A patent/BRPI0607433A2/pt not_active IP Right Cessation
- 2006-02-24 US US11/817,088 patent/US20090088419A1/en not_active Abandoned
- 2006-02-24 AR ARP060100686A patent/AR055563A1/es not_active Application Discontinuation
- 2006-02-24 PE PE2006000223A patent/PE20061099A1/es not_active Application Discontinuation
- 2006-02-24 WO PCT/JP2006/304177 patent/WO2006090915A1/en active Application Filing
- 2006-02-24 RU RU2007135339/04A patent/RU2007135339A/ru not_active Application Discontinuation
-
2007
- 2007-08-20 IL IL185399A patent/IL185399A0/en unknown
- 2007-09-05 CR CR9369A patent/CR9369A/es not_active Application Discontinuation
- 2007-09-10 MA MA30205A patent/MA29323B1/fr unknown
- 2007-09-13 NO NO20074668A patent/NO20074668L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20070106794A (ko) | 2007-11-05 |
CN101166725A (zh) | 2008-04-23 |
IL185399A0 (en) | 2008-02-09 |
MA29323B1 (fr) | 2008-03-03 |
ZA200708144B (en) | 2008-11-26 |
CR9369A (es) | 2007-10-22 |
AR055563A1 (es) | 2007-08-22 |
NO20074668L (no) | 2007-11-15 |
CA2598934A1 (en) | 2006-08-31 |
EP1851202A1 (en) | 2007-11-07 |
RU2007135339A (ru) | 2009-03-27 |
PE20061099A1 (es) | 2006-12-05 |
TW200640862A (en) | 2006-12-01 |
AU2006217677A1 (en) | 2006-08-31 |
WO2006090915A1 (en) | 2006-08-31 |
US20090088419A1 (en) | 2009-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607433A2 (pt) | composto ou um sal do mesmo, pró-droga, agente farmacêutico, inibidor de peptidase, uso de um composto ou de uma pró-droga do mesmo, e, métodos de prevenção ou tratamento de doenças, de inibição de peptidase em um mamìfero, e de produção de um composto | |
BRPI0612072A2 (pt) | inibidores da aspartil protease | |
MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
CO6150162A2 (es) | Pirrolopirimidinas para composiciones farmaceuticas | |
MX2010008460A (es) | Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular. | |
MX2011011335A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina. | |
MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
NZ598242A (en) | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer | |
DE602005004286D1 (de) | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs | |
MX2007015863A (es) | Inhibidores de esfingosina cinasa. | |
BR112014000240A2 (pt) | derivados de benzilamina como inibidores de calicreína plasmática | |
WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
GEP20125537B (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
BRPI0514841A (pt) | inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores | |
BR112012015714A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença neurodegenerativa, método para reduzir a concentração de p-ser-alfa-sinucleina em tecido cerebral, e, método para o tratamento de um câncer | |
TW201000473A (en) | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | |
TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
GEP20125459B (en) | Compounds for inhibiting mitotic progression | |
BR112013010310A2 (pt) | inibidores de acetil-coa carboxilase de lactama n1/n2 | |
HK1138262A1 (en) | Novel phosphodiesterase inhibitors | |
MX2009005201A (es) | Derivados de estratrieno sustituidos como inhibidores de 17beta hsd. | |
TN2010000038A1 (en) | Organic compounds | |
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
AR052413A1 (es) | Nuevos derivados de piridotienopiriidina | |
MX2008016358A (es) | Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |